Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human IL34 Antibodies:
anti-Mouse (Murine) IL34 Antibodies:
anti-Rat (Rattus) IL34 Antibodies:
Go to our pre-filtered search.
Human Polyclonal IL34 Primary Antibody for ELISA, WB - ABIN1002640
Lin, Lee, Hestir, Leo, Huang, Bosch, Halenbeck, Wu, Zhou, Behrens, Hollenbaugh, Linnemann, Qin, Wong, Chu, Doberstein, Williams: Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. in Science (New York, N.Y.) 2008
Human Monoclonal IL34 Primary Antibody for ICC, FACS - ABIN969216
Slomiany, Baker, Elliott, Grossel: Changes in motility, gene expression and actin dynamics: Cdk6-induced cytoskeletal changes associated with differentiation in mouse astrocytes. in Journal of cellular biochemistry 2006
Human Monoclonal IL34 Primary Antibody for FACS - ABIN4896347
Bézie, Picarda, Ossart, Tesson, Usal, Renaudin, Anegon, Guillonneau: IL-34 is a Treg-specific cytokine and mediates transplant tolerance. in The Journal of clinical investigation 2015
Data showed that single expression of M-CSF (show CSF1 Antibodies) or IL-34 can be observed in lung cancer tissues and correlated with poor survival. Additionally, their high co-expression correlates with disease stages and poor survival. Thus, evaluating the expression of both M-CSF (show CSF1 Antibodies) and IL-34 may help to estimate disease progression and malignant degree in lung cancer patients.
this study shows that IL-34 regulates IL-6 (show IL6 Antibodies) and IL-8 (show IL8 Antibodies) production in human lung fibroblasts via MAPK (show MAPK1 Antibodies), PI3K (show PIK3CA Antibodies)-Akt (show AKT1 Antibodies), JAK (show JAK3 Antibodies) and NF-kappaB (show NFKB1 Antibodies) signaling pathways
Study indicates that IL-34 can be an indicator of liver inflammation and fibrosis in patients with chronic hepatitis B virus infection.
In conclusion, elevated serum IL-34 levels were demonstrated to be independently associated with renal insufficiency and coronary artery disease in patients with chronic heart failure, regardless of the systolic function.
Data indicate that the interleukin 34 (IL-34) is a feasible diagnostic marker of liver fibrosis in non-alcoholic fatty liver disease (NAFLD (show TSC2 Antibodies)) patients.
Findings uncover a novel function for IKKbeta (show IKBKB Antibodies)/mHTTx1 interactions in regulating IL-34 production, and implicate a role for IL-34 in non-cell-autonomous, microglial-dependent neurodegeneration in HD.
The IL-34/STAT3 (show STAT3 Antibodies)/miR (show MLXIP Antibodies)-21 pathway is crucial for the survival of synovial fibroblasts in rheumatoid arthritis
Data show that both serum interleukin-34 (IL-34) and IL-34 mRNA in mononuclear leukocytes (PBMCs) in chronic hepatitis B virus (HBV) patients was significantly decreased compared to the healthy controls.
pathogenic role for IL34 in mediating immunosuppression and chemoresistance and identify it as a tractable target for anticancer therapy.
The current study aimed to assess the IL-34 expression in response to two members of the transforming growth factor (TGF)-beta family, TGF-beta1 and bone morphogenetic protein (BMP)-2, in synovial fibroblasts from rheumatoid arthritis patients.
study concludes that Langerhans cells require IL-34 when residing in fully differentiated and anatomically intact skin epidermis, but rely on neutrophil-derived CSF1 (show CSF1 Antibodies) during inflammation
constitutive IL-34 expressed by skin keratinocytes might suppress resident macrophage responses to C. albicans colonisation by maintaining low levels TLR2 and Dectin-1 (show CLEC7A Antibodies) expression by macrophages.
IL-34 protected blood-brain barrier integrity by restored expression levels of tight junction proteins, which were downregulated by pro-inflammatory cytokines.
IL-34-dependent, Mo-mediated, CSF-1 (show CSF1 Antibodies) nonredundant mechanisms promote persistent ischemia-incited AKI that worsens subsequent CKD.
In vitro and in vivo experiments indicate that IL-34 expression is regulated by TNF-a (show TNF Antibodies) and IL-1b (show IL1B Antibodies) and that its overexpression is associated with an increase in osteosarcoma growth and metastasis.
the expression pattern of IL-34 in ileum and colon and suggest IL-34 as a new modulator of inflammation in inflammatory bowel disease
Tumor necrosis factor-alpha (show TNF Antibodies) induces IL-34 expression via NF-kappaB (show NFKB1 Antibodies) in MC3T3-E1 osteoblastic cells.
These findings suggest that TGF-beta (show TGFB1 Antibodies) produced by IL-34-treated microglia is a negative regulator of microglial proliferation and enhances the neuroprotective property of microglia.
Differentiated signaling between IL-34 and CSF-1 (show CSF1 Antibodies) is likely achieved by the relative thermodynamic independence of IL-34 versus negative cooperativity of CSF-1 (show CSF1 Antibodies) at the CSF-1 receptor (show CSF1R Antibodies) recognition sites.
Interleukin-34 is a cytokine that promotes the differentiation and viability of monocytes and macrophages through the colony-stimulating factor-1 receptor (CSF1R\; MIM 164770) (Lin et al., 2008